Research Papers:

Comparison of isolation platforms for detection of circulating renal cell carcinoma cells

Yvonne Maertens, Verena Humberg, Franziska Erlmeier, Sandra Steffens, Julie Steinestel, Martin Bögemann, Andres Jan Schrader and Christof Bernemann _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:87710-87717. https://doi.org/10.18632/oncotarget.21197

Metrics: PDF 1823 views  |   HTML 3135 views  |   ?  


Yvonne Maertens1, Verena Humberg1, Franziska Erlmeier2, Sandra Steffens1, Julie Steinestel1, Martin Bögemann1, Andres Jan Schrader1 and Christof Bernemann1

1Clinic for Urology, University Hospital Muenster, Muenster, Germany

2Institute for Pathology and Pathological Anatomy, Technical University Munich, Munich, Germany

Correspondence to:

Christof Bernemann, email: [email protected]

Keywords: clear cell renal cell carcinoma, circulating tumor cells, biomarker, liquid biopsy, genitourinary cancer

Received: June 15, 2017     Accepted: August 25, 2017     Published: September 23, 2017


Background: Analysis of circulating tumor cells (CTCs) has progressed in several tumor entities. However, little is known about CTCs in clear cell renal cell carcinoma (ccRCC) patients. Aim of our studies was to build a stable in vitro fundament for isolation of CTCs in ccRCC.

Methods: We compared the analytical performance of different CTC isolation methods with regard to yield and purity: EpCAM based enrichment, leukocyte depletion and size based enrichment. EpCAM and cytokeratin 8 (KRT8) as biomarker for CTCs expression were evaluated in ccRCC cell lines as well as clinical samples.

Results: While the EpCAM based approach failed to successfully isolate tumor cells, CD45 based approaches showed intermediate recovery rates. The cell-size based Parsortix system showed highest recovery rates. EpCAM expression was low or absent in most cell lines as well as in clinical samples, whereas KRT8 was detected as a potential biomarker in ccRCC.

Conclusion: EpCAM based approaches might miss a high number of CTCs due to low or absent expression of EpCAM in ccRCC, as shown in cell lines as well as in patient samples. We identified the cell-sized based, label independent Parsortix system to be the most effective recovery system for ccRCC CTCs.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21197